Increased dose primary thromboprophylaxis in ambulatory patients with advanced pancreatic ductal adenocarcinoma, a single centre cohort study.

Anthony Maraveyas (✉ anthony.maraveyas@hey.nhs.uk)  
University of Hull  
https://orcid.org/0000-0003-4176-5176

Farzana Haque  
Hull University Teaching Hospitals NHS Trust

Iqtedar Ahmed Muazzam  
Hull University Teaching Hospitals NHS Trust

Waqas Ilyas  
Hull University Teaching Hospitals NHS Trust

George Bozas  
Hull University Teaching Hospitals NHS Trust

Research

Keywords: Pancreatic Cancer, Thromboprophylaxis, Dalteparin, Ambulatory, Chemotherapy

Posted Date: May 18th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-16436/v2

License: ☒ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License

Version of Record: A version of this preprint was published at Thrombosis Journal on May 29th, 2020.  
See the published version at https://doi.org/10.1186/s12959-020-00222-1.
Abstract

Background: Advanced pancreatic ductal adenocarcinoma (aPDAC) patients have a lifetime all type thromboembolic event (ATTE) rate of 25-35%. Efficacy and safety of increased dose primary thromboprophylaxis (IDPTP) with low molecular heparin (LMWH) given for 3 months has been shown in two prospective randomized trials. Objectives: To report on efficacy - reduction of all type thromboembolic events (ATTE) - safety - incidence of Major Bleeding (MB) - and compliance in a single-centre cohort of receiving first line chemotherapy and LMWH-IDPTP.

Methods: From May 2009 to October 2016, eighty two patients received IDPTP –LMWH with dalteparin. Schedule: 55kg and below: 7500 IU, between 55 and 80kg: 10,000 IU, above 80kg: 12,500 IU. MB is reported using the International Society of Thrombosis and Haemostasis (ISTH) criteria. ATTE was defined as any arterial or venous event, incidental or clinically symptomatic, including visceral VTE.

Results: Mean and median time on dalteparin was 10.2 (95%CI 8.1, 12.4) and 8.0 (95%CI 6.2, 9.7) months respectively. ATTE was observed in 7 (8.5%) of patients, with a median time on IDPTP of 6.2 months (95% CI 10.0, 13.2). MB was seen in 10 (12.2%) patients with a median time on IDPTP of 4.5 months (95% CI 1.6–7.4). Six major bleeds (60%) were the direct or indirect result of aPDAC. Eighty-one patients had died at the time of data collection with a median overall survival time of 8.7 months (95%CI 6.4, 11.0). Thromboembolism and bleeding were late events. No impact of thromboembolism or bleeding on overall survival was observed.

Conclusions: IDPTP-dalteparin was associated with lower ATTE occurrence rates than expected and comparable major bleeding rates. ATTE and MB were late events; the majority of MB was from direct or indirect result of locally progressing aPDAC. Since these conditions can frequently arise in aPDAC, IDPTP should be regularly reviewed beyond 3 months.

Introduction

Patients with advanced pancreatic ductal adenocarcinoma (aPDAC) have a seven-fold increased risk of developing arterial and venous thromboembolism as compared to patients with most other solid and haematological malignancies(1, 2). This translates to about one-third of patients with aPDAC suffering from either a clinically evident or unsuspected (incidental) thrombo-embolic event (TE) over short life spans, and the spectrum of these events is broad, ranging from the conventional venous thromboembolism (VTE) of deep vein thrombosis(DVT)-pulmonary embolism (PE) complex, to arterial as well as visceral thromboses(3). The manifestation of a VTE, apart from the physical and psychological burden inflicted on the cancer patient, generally results in increased health utilization costs of up to 45% per affected cancer patient (4) with VTE incremental costs being the highest in pancreatic cancer patients (5).

The administration of chemotherapy in ambulatory aPDAC patients is an additional risk factor for thromboembolism which further complicates an already challenging management (3). A modest
improvement in survival has been seen with new chemotherapy combinations (6) but they have also resulted in increased VTE risk (7). The use of currently available anticoagulant agents reduces VTE risk and their efficacy has been proven in randomized trials (8,9). Current guidelines from major international bodies have changed recently to suggest that patients with Khorana Score 2 and above should be considered for thromboprophylaxis. This by definition includes patients with pancreatic cancer (10-12). These guidelines have been updated following the studies AVERT(13) and CASSINI (14) and now include the option of using a direct oral anticoagulant (DOAC). The recent (2018) NICE guidance also suggests that thromboprophylaxis should be considered in aPDAC (13). Both the FRAGEM study (8) with a 19.6% absolute difference in thromboembolic rates and a number needed to treat (NNT) of 5 and CONKO-04 (9) with an absolute difference of 8.7% in thromboembolic rate and a NNT of 11 provide meaningful clinical benefit.

These studies used increased dose primary thromboprophylaxis (IDPTP) for 3 months. The investigators in CONKO 004 used a two-third -therapeutic dose of enoxaparin (1mg/kg once daily) for the first 3 months, followed by conventional primary prophylaxis maintenance of 40mg sc. once daily. The investigators in FRAGEM used full therapeutic dose schedule of dalteparin (200u/kg once daily for 4 weeks reduced to 150u/kg once daily) for the first 3 months at which point thromboprophylaxis was discontinued.

None of the current guidelines offer a clear opinion on LMWH dosing though the ASCO guideline mentions that the studies of LMWH thromboprophylaxis in pancreatic cancer patients were conducted at a ‘treatment dose’ of LMWH (10) otherwise termed ‘supra-prophylactic’ (16).

Soon after the LMWH–related data were first published Hull University Teaching Hospitals (HUTH) implemented a dalteparin-based thromboprophylaxis schedule for aPDAC patients using a supra-prophylactic dosing approach. It is this single-centre retrospective real-world cohort series experience in ambulatory aPDAC patients that we present here.

Objectives: To report efficacy, safety and compliance in a real-world cohort of consecutively treated patients with advanced and metastatic pancreatic cancer receiving an increased dose primary thromboprophylaxis (IDPTP) schedule of dalteparin.

Patients And Methods

A) Increased dose primary thromboprophylaxis (IDPTP) schedule

For aPDAC patients deemed fit for systemic treatment we implement a simplified dalteparin increased thromboprophylaxis schedule, close to the 75% full therapeutic dose of the CLOT schedule used in the FRAGEM trial and in accordance with the CONKO-04 scheduling of continuing thromboprophylaxis throughout chemotherapy but without mandating a switch to conventional dose or discontinuation.
The IDPTP dalteparin schedule was weight adjusted and ranged as follows. For patients 55kg and below: 7500 IU, for patients between 55 and 80kg: 10,000 IU and for patients above 80kg: 12,500 IU.

B) Patients

The HPB-MDT database (Taunton & Somerset NHSFT QGCE 1499) was searched for all pancreatic cancer patients that were referred to the cancer centre between May 2009 and October 2016, and then cross referenced with the electronic chemotherapy database (ARIA MedOnc 13.7). Patients were further cross referenced through the electronic medical record system (iSOFT Patient Centre®, CSC™ and Lorenzo®, CSC™) and through the pharmacy dispensary database (Ascribe RX™) for all the outpatient prescriptions for anticoagulants. From these electronic medical records demographic, historic, cancer therapy and cancer specific data were collected for each patient in a retrospective manner. All patients had histological/cytological proof of ductal adenocarcinoma of the pancreas with inoperable locally advanced or metastatic cancer and a multi-disciplinary team (MDT) decision for systemic treatment. Only patients due to receive first line treatment were included. Accordingly, patients had to have haematological and biochemical indices allowing systemic treatment for their cancer to be eligible for treatment with IDPTP. Non-ambulatory patients or patients not considered for systemic cancer treatment either due to performance status or non-alleviated cancer morbidity (e.g. non-relievable obstruction of biliary tree or duodenal outlet) were excluded. Patients with any contraindications for anticoagulation (dalteparin) were excluded. Patients receiving other anticoagulation (e.g. a direct oral anticoagulant or warfarin) and not transferred to IDPTP were excluded.

C) Outcome Measures

Primary aim of the study was to determine the occurrence rate of all type thromboembolic events (ATTE) and rate of major bleeding (MB). ATTE was defined as any TE event -arterial or venous, incidental or clinically symptomatic including visceral VTE and is reported in this manuscript as ATTE or TE. VTE is used for conventional PE/DVT definitions. All recorded ATTE and bleeding events were reviewed by three of the authors (AM,GB &IM) and the nature, severity and classification agreed. Bleeding episodes were classified into major and minor by ISTH criteria. Major bleeding was defined as any fatal bleeding, symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in haemoglobin level of 20 g L\(^{-1}\) (1.24 mmol L\(^{-1}\)) or more, or leading to transfusion of two or more units of whole blood or red cells (17). Compliance to anticoagulant treatment was inferred from the time and length of the last recorded outpatient or ward prescription chart.
E) Approvals & Statistics

The study reported in this manuscript is the result of work that has been classified as an audit. This is a regular undertaking in UK hospitals with the primary goal of maintaining quality standards and identifying areas that need improvement if they fall below accepted standards as set by national or international guidelines. Audits can be retrospective or prospective. As per the NHS Health Research Authority guidelines our study, which can be classified within the audit / service evaluation description, does not require external Research Ethics Committee approval [18]. The NHS Trust governance body which authorises the project is doing so if the study is conducted within the regulatory framework including the Data Protection Act (1998), the Caldicott principles (1997) and the NHS Confidentiality code of practice (2003) [19]. Within this context regulatory approval is sought and obtained based on the quality of the audit and the priority of the area studied and whether it fits within the quality framework of the organization. The endorsement code for our study is 2017.98 issued by the Hull and East Yorkshire Hospitals NHS Trust approved the 1st June 2017.

Patients were registered sequentially on the database. Data were collected in an MS EXCEL®2010 (Microsoft Corp™) spread sheet maintained in a secure virtual hard-drive with restricted access. All analyses were performed with SPSS ver22, IBM Corp ®. Descriptive statistics were used to analyse patient characteristics. Data on the TE-free interval (TFI) and bleeding-free interval (BFI) were reported in months from the time of commencing IDPTP up to the index event (last follow-up contact or the date of death). The collected data was also used to calculate the median overall survival of the whole study population and whether TE and bleeding episodes had demonstrated any impact on survival. No patients were lost to follow-up. To correct for competing risk of death the rate of TE or major bleeding for the time intervals was calculated as the number of events divided by the total number of patients at risk (subject months). The Clopper-Pearson method was used for 95% confidence interval. The Kaplan Meier method was utilised to explore the prognostic significance of categorical variables using the log rank test to compare factors.

Results

One hundred and one patients with aPDAC were registered on the database. The search process also identified patients with prior VTE either before cancer diagnosis or during adjuvant treatment for PDAC, patients with concurrent diagnosis of TE and aPDAC or patients on long term anticoagulants due to pre-existing AF(atrial Fibrillation) or unprovoked VTE having been switched to an IDPTP schedule (details in Flow chart Figure 1)

Demographics and event rates are reported for the whole cohort but the detailed analyses are restricted to the 82 patients that corresponded to an entirely IDPTP cohort.

The median age was 67 years, interquartile range: 61-72 (n=82) and 54% were male. Sixty five per cent of these patients were metastatic and the rest locally advanced. Ninety-six patients were offered first line
chemotherapy. Sixty nine per cent of the patients received only one line of treatment, 20% received two lines of treatment and only 2% received a third line of treatment.

Of the IDPTP cohort (N=82) sixty-four patients (78%) were offered Gemcitabine based first line treatment (48 patients (58%) single agent gemcitabine & 16 (20%) first line gemcitabine-based combination) and 18 patients FOLFIRINOX.

The baseline characteristics of all patients, for the 82 IDPTP patients and the primary endpoint data are shown in Table 1.

In the IDPTP cohort (n=82), patients remained on thromboprophylaxis for a median duration of 8.0 months, 95% CI (6.2, 9.7). Seven patients [8.5%, 95%CI (3.7,14.6)] developed a TE despite IDPTP and ten patients [12.2%, 95%CI (6.1,19.5)] in the IDPTP group had a major bleed and 2 patients [2.4% 95%CI (0.6,1)] had a minor bleed, for a combined event rate of major bleeding and TE of 18% [n=15/82 as two patients had a TE and a bleed, 95%CI (9.8,26.80)]. The correlation between the IDPTP and the timing of TE and bleeding can be seen in Figure 2. The cumulative rates of MB at 3 and 12 months of this real-world cohort are compared to the experimental arms of FRAGEM and CONKO-04 where data were available (Table 2). Figure 2A&B present the cumulative hazard of developing a breakthrough TE or bleed. The accelerated phase of the cumulative hazards plot is between 4 and 8 months which is later than the conventional first three months seen in patients without thromboprophylaxis, reflecting the median time to TE of 6.2 months (95% CI 10.0, 13.2). This can be seen most clearly in Figure 2C where the data are corrected for competing risk of death. A similar late pattern is noted for the major bleeding episodes median time to MB 4.5 months (95% CI 1.6, 7.4). The majority of the minor and major bleeding events were upper GI (8/14, 57%) and were directly or indirectly attributable to an aPDAC related cause.

Median overall survival time from commencement of IDPTP was 8.7 months, 95% CI, (6.4, 10.9). Neither thrombotic events [12.2 months, 95% CI (10.7, 13.7) Vs 8.4 months, 95% CI (6.9, 9.9) (p = 0.79)] nor bleeding events [median 8.7 months, 95% CI (6.4, 17) Vs 8.4 months, 95% CI (5.8, 11) (p = 0.94)] affected survival outcome. Progressive cancer remained the major cause of death (70 out of 82; 85%) as reported in the death certificate and agreed by the investigators. Five of these patients were found to be suffering from MB as a tumour progression-related event during the process of dying from cancer, the context often informing decision making (e.g. restraint on endoscopic or other invasive procedures or reflection on futility of transfusion). For one patient bleeding (uterine) was reported in the death certificate and confirmed by the investigators as the direct cause of death (1.2%). Two patients suffered a fatal thromboembolic event (2.4%). One a CVA and one a pulmonary infarct. Figure 4 charts MB and ATTE in the relevant patients, their timing and their link to the presence or absence of IDPTP over the patient life-span.

**Discussion**

In this study we show that the 12 month rate of TE (8.5%) is on a par with the TE rate seen in the experimental arm of the FRAGEM study (12%) and much lower than the control arm of FRAGEM (24%). It is also much lower than in historical series (25-35%) (20). We also show an incidence of clinically
apparent VTE rate (PE and DVT) is 4.8%, similar to CONKO-04 (5.7%) and lower than in FRAGEM (8.4%) (Table 2).

The existing RCT evidence pertains to patients receiving first line chemotherapy Gemcitabine either as a single agent or in combination with a platinum (8,9). In this study 42% of patients received the more modern combinations of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin) or AG (Abraxane, Gemcitabine). These chemotherapy schedules do not seem to have a diminished thrombosis risk. FOLFIRINOX has a 60% increase in risk of VTE (6.6% compared to gemcitabine alone 4.1%) (21). In the study HALO-109-202 the rate of VTE in the investigational arm (AG-PEGPH20) was 42% and control arm (Gem Abraxane) was 25% respectively in stage 1 of the trial (22). 40 mg of enoxaparin saw no VTE reduction in either arm. Only when an enoxaparin-IDPTP schedule was implemented did VTE rate drop to 5% and 6% respectively. A LMWH scale of dose-effectiveness in pancreatic cancer patients has recently been reported and can aid in decision making on IDPTP (7).

Compliance has been shown to be better with oral agents with large early discontinuation rates for LMWHs (25). Although injectable anticoagulants are undoubtedly more invasive than a tablet, patient views are nuanced. At least 2 studies (26, 27) have shown that patients will select anticoagulants that are least likely to interfere with their cancer treatment. In the SELECT-D sub-study (27) patients did express a preference for an oral agent, but only if this has equivalent clinical benefit to LMWH. Compliance in this study was very high, with patients staying on dalteparin for a median of 8.0 months. This may also reflect the absence of an alternative oral option in the IDPTP setting.

Very recently an experience of therapeutic dose rivaroxaban (15 mg po bd followed by 20 mg po od) in 28 aPDAC patients receiving Gemcitabine Abraxane showed a 7% major bleeding (2/28) and one breakthrough VTE (asymptomatic) 3.5 % (28). Though promising there are no randomised data in this setting for supraprophylactic DOAC schedules and one has to be aware of the greater propensity of the GI tract cancers to be associated with increased non-major but clinically relevant bleeding as seen in the recent studies of cancer associated thrombosis treatment with rivaroxaban and edoxaban (29,30).

Two RCTs using conventional thromboprevention schedules of the direct oral anticoagulants rivaroxaban and apixaban in cancer patients have recently published (13,14).

Patients were risk stratified using the Khorana risk stratification score. In the CASSINI study 54% of patients had either aPDAC(33%) or Gastroesophageal (GO) (21%) while in the AVERT study only 16% belonged to this group (13% aPDAC and 3% GO). Efficacy endpoint sub-analysis (prevention of VTE) for the aPDAC patients has been published only for the CASSINI study (HR 0.70, 95%CI 0.344,1.432). The latest iteration of most guidelines (2019) reinforced by the 2 recent randomised studies of DOACS, have formulated thromboprophylaxis recommendations for aPDAC (10,11). As the data stand LMWH-IDPTP schedules remain a proven approach for aPDAC while for the DOACs there remains the need for a well-designed single cancer RCT (31).
Conclusion

In conclusion we demonstrate that, an IDPTP-LMWH with dalteparin reflecting the evidence can be implemented and patients can adhere to it. IDPTP-LMWH was associated with lower ATTE occurrence rates than expected and comparable major bleeding rates. ATTE and MB were late events; the majority of MB was from the GI tract and the direct or indirect result of locally progressing aPDAC. Since these conditions can frequently arise in aPDAC, IDPTP-LMWH beyond 3 months needs to be approached cautiously and should be regularly reviewed due to the increasing risk of GI bleeding in late–progressing pancreatic cancer.

Abbreviations

AG = Abraxane, Gemcitabine; aPDAC = Advanced Pancreatic Ductal Adenocarcinoma; ATTE = All type Thromboembolic Events; BFI = bleeding-free interval; DOAC = Direct Oral Anticoagulant; DVT = Deep vein Thrombosis; ECOG-PS Eastern Cooperative Group Performance status; FOLFIRINOX = Folinic Acid, 5-Fluorouracil, Irinotecan, Oxaliplatin; GI = Gastrointestinal; GO (Gastro-oesophageal); IPE = Incidental Pulmonary Embolism; IDPTP = Increased Dose Primary Thromboprophylaxis; LMWH = Low Molecular Weight Heparin; MB = Major Bleeding; NNT Numbers Needed to Treat; PE = Pulmonary Embolism; PEGPH20 = Pegvorhyaluronidase Alfa; TE = Thromboembolic Event; TFI = TE-free interval; VTE = Venous Thromboembolism

Additional Information & Declarations

Ethical Approval and Consent to participate (see methods – section E- for details):

Endorsement code for audit is 2017.98 issued by the Hull and East Yorkshire Hospitals NHS Trust approved the 1st June 2017. The study was performed in accordance with the data Protection Act (1998), the Caldicott principles (1997) and the NHS Confidentiality code of practice (2003) that all comply with the requirements of the declaration of Helsinki

Consent for publication = N/A

Availability of supporting data: Database of all 101 patients and statistical analyses available upon request and authorization from HEYNHST R&D.

Competing interests & Conflicts:

FH, IM, WI and GB have no conflicts of interest in relation to this work.

AM has received fees for speaker’s bureau, consultancy and travel from Pfizer (Dalteparin)

Funding = N/A
Author's contributions:

AM Conceived the study, reviewed data, adjudicated/reconciled events and wrote the manuscript

FH Cleaned the data, analysed the data and reviewed the manuscript

IM developed the audit proposal, collected data, cleaned the data and reviewed the manuscript

WI Co-developed the audit proposal, collected data, developed the database, cleaned the data and reviewed the manuscript and submitted final audit report.

GB Analysed the data, adjudicated/reconciled events and reviewed the manuscript

All Authors approved the final manuscript

Acknowledgements:

We would like to thank Sarah Scargill for pharmacy crosschecking and Anita Gadie for support with the search of the HPB-MDT database.

References

1. Maraveyas A. Pancreatic cancer: A model cancer for the study of the therapeutic effects of anticoagulants. *World J Gastroenterol.* 2009; 1: 38-40.

2. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. *Lancet Oncol.* 2004 Nov;5(11):655-63

3. Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. *Thromb Haemost.* 2011 Aug;106(2):371-8

4. Lyman GH, Eckert L, Wang Y, Wang H, Cohen A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. *Oncologist.* 2013; 18: 1321-9. 10.1634/theoncologist.2013-0226.

5. Khorana AA, Dalal MR, Lin J, Connolly GC. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. *Clinicoecon Outcomes Res.* 2013; 5: 101-8.

6. Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. *Panreatology.* 2015 Jan-Feb;15(1):8-18

7. Maraveyas A, Muazzam I, Noble S, Bozas G. Advances in managing and preventing thromboembolic disease in cancer patients. *Curr Opin Support Palliat Care.* 2017 Dec;11(4):347-354.
8. Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F., et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. *Eur J Cancer*. 2012; 48: 1283-92.

9. Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S., et al. Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. *J Clin Oncol.* 2015; 33: 2028-34.

10. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP., et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol.* 2013; 31: 2189-204.

11. National Comprehensive Cancer Network Venous Thromboembolic Disease Clinical Practice Guidelines in Oncology. v.1.2015 edn. [www.nccn.org](http://www.nccn.org): NCCN, 2015, Guideline.#

12. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, et al International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013 Jan;11(1):56-70.

13. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al CASSINI Investigators. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.N Engl J Med. 2019 Feb 21;380(8):720-728.

14. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019 Feb 21;380(8):711-719.

15. Venous thromboembolism in over 16s: reducing the risk of hospital acquired deep vein thrombosis or pulmonary embolism : NICE guidline 21 March 2018 https://www.nice.org.uk/guidance/ng89

16. Ek L, Gezelius E, Bergman B, Bendahl PO, Anderson H, Sundberg J, Wallberg M, Falkmer U, Verma S, Belting M; Swedish Lung Cancer Study Group (SLUSG). Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial. Ann Oncol. 2018 Feb 1;29(2):398-404

17. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692-4.

18. HRA. *Defining Research. NHS Health Reresearch Authority.* 2017. [http://www.hra-decisiontools.org.uk/research/docs/DefiningResearchTable_Oct2017-1.pdf](http://www.hra-decisiontools.org.uk/research/docs/DefiningResearchTable_Oct2017-1.pdf). Accessed 30 Dec 2017.

19. HQIP (2016) Best practice in clinical audit. Health quality improvement partnership [http://www.hqip.org.uk/resources/best-practice-in-clinical-audit-hqip-guide/](http://www.hqip.org.uk/resources/best-practice-in-clinical-audit-hqip-guide/). Accessed 30 Dec 2017.

20. Campello, E., Ilich, A., Simioni, P. et al. The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. Br J Cancer 121, 359–371 (2019). https://doi.org/10.1038/s41416-019-0510-x

21. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med.* 2011; 364: 1817-25. 10.1056.
22. Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, et al. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J Clin Oncol. 2018 Feb 1;36(4):359-366.

23. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013 Feb 1;119(3):648.

24. Wang YU, Yuan C, Liu X. Characteristics of gastrointestinal hemorrhage associated with pancreatic cancer: A retrospective review of 246 cases. Mol Clin Oncol. 2015 Jul;3(4):902-909.

25. Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberté F, et al Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. Res Pract Thromb Haemost. 2017 May 30;1(1):14-22.

26. Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G. Assessing patients’ anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica. 2015 Nov;100(11):1486-92.

27. Hutchinson, A. Rees, S. Young, A. Maraveyas, A. Date, K. Johnson MJ. Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial. Pal Med (Manuscript accepted for publication)

28. Yu KH, Mantha S, Tjan C, Kaufmann ES, Brenner R, Lowery MA. Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis. J. Clin Onc. 2018 36 no.4_suppl 405-405

29. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor with Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017-2023

30. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-624

31. Agnelli G. Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer. N Engl J Med. 2019 Feb 21;380(8):781-783.

**Tables**

**Table 1**
|                          | Miscellaneous TP | IDPTP |
|--------------------------|------------------|-------|
| **Patients**             | 19               | 82    |
| Age (years)              | 71 (r41)         | 67 (r51) |
| Male                     | 11 (58%)         | 43 (52%) |
| Metastatic               | 10 (53%)         | 56 (68%) |
| WHO PS 0-1               | 10 (53%)         | 67 (82%) |
| **Chemotherapy**         | **14 (73%)**     | **82 (100%)** |
| FOLFIRINOX               | 2 (10%)          | 18 (22%) |
| Gemcitabine SA           | 10 (52%)         | 48 (58%) |
| Gem-Based Combi          | 1 (5%)           | 16 (20%) |
| No Chemo                 | 5 (27%)          | -     |
| **Events (Bleeding)**    | **4 (20%)**      | **12 (14.5%)** |
| #Major Bleeding          | 2 (10%)          | 10 (12.2%) |
| Upper GI bleed           | 2 (100%)         | 7 (70%) |
| Lower GI bleed           | -                | 2 (20%) |
| Genitourinary            | -                | 1 (10%) |
| #Minor Bleeding          | 2 (10%)          | ***2 (2.5%) |
| **Events (AT-TE)**       | **7 (37%)**      | **7 (8.5%)** |
| DVT                      | 2                | 2     |
| i-PE                     | 2                | 2     |
| PE                       | -                | 1     |
| i-PE & DVT               | -                | 1     |
| CVA                      | 2                | 1     |
| DVT & Visceral           | 1                |       |

*One patient was treated with adjuvant chemotherapy (5FU/LV)
**73% completed one line, 24% two lines & 2.4% three lines of chemotherapy
*** 1 minor bleed was upper GI
Table 2

| EVENTS (Cumulative Incidence)          | CONKO-04   | FRAGEM  | SC-IDPTP |
|----------------------------------------|------------|---------|----------|
| Major Bleed (3 Months)                 | 4.5% (7/160) | 3% (3/59) | 2.4% (2/82) |
| Major Bleed (12 months)                | 8.3% (13/160) | -       | 9.7% (8/82) |
| Breakthrough PE/DVT (12 months)        | 5.7% (9/160) | *8.4% (5/59) | **4.8% (4/82) |
| Breakthrough All type TE (12 months)   | -          | 12% (7/59) | 8.5% (7/82) |

*Excludes 2 cases of I-PE to be comparable to CONKO-04

**Excludes 2 cases of I-PE and the CVA so as to be comparable to CONKO-04

Figures

Figure 1

1) Study Flow Chart. Patients that were identified using the search strategy described in the methods were entered on to a data base. Their case notes were reviewed and the patients that bore similarities to
the experimental cohort of patients treated in the FRAGEM (8) and CONKO-04 (9) studies were selected for further analyses (IDPTP group). The miscellaneous reasons for exclusion are detailed. (ACS= Acute Coronary Syndrome, AF= Atrial Fibrillation, aPDAC= advanced Pancreatic Ductal Adenocarcinoma, BSC= Best Supportive Care, CVA= Cerebrovascular Accident, DVT= Deep Vein Thrombosis, GI= Gastrointestinal, iPE = Incidental Pulmonary Embolism, LMWH= Low Molecular Weight Heparin, PE= Pulmonary Embolism, SC-IDPTP = Study Cohort of Increased Dose Primary Thromboprophylaxis, TE= Thromboembolic Event, TP= Thromboprophylaxis, VTE=Venous Thromboembolism)

Figure 2

2) The Hazard Plots (Kaplan Meier) for: (A) TE events, (B) Major Haemorrhage for the first twelve months of follow-up of 82 patients on IDPTP. (C) Incidence of thromboembolic events (TE) and Major Bleeding at different time periods. A lower incidence of TE is seen during the 1st 3 months, 0.4% (95% CI 0.0, 2.4; 1/226 subject months), compared to 2.1% (95% CI 0.4, 5.9; 3/146 subject months) after 8 months (the median duration of thromboprophylaxis in this group). A similar pattern is notable for major bleeding. Incidence was less in the 1st 3 months, 0.9% (95% CI 0.1, 3.1; 2/227 subject months). During the 4-8 months period (280 subject months), 5 patients experienced a major bleeding event that gives an incidence of 1.8% (95% CI 0.6, 4.1). Comparable to that, 3 patients (146 subject months) had major bleed after 8 months with an incidence of 2.1% (95% CI 0.4, 5.9)
Figure 3

3) Cumulative Thromboembolic Events (TEs) graph comparing TE occurrence in the two FRAGEM study arms (8) to the TE occurrence in the SC IDPTP. (SC-IDPTP = Study Cohort of Increased Dose Primary Thromboprophylaxis, TE= Thromboembolic Event)
Figure 4

4) The 15 patients with events. The sequential database numbers have been retained. (GI= Gastrointestinal, iPE = Incidental Pulmonary Embolism).